Search - tctmd.com

Displaying 381 - 400 of 671

Sort: Relevancy | Date

Presentation

Optimizing P2Y12-Receptor Inhibition in ACS Patients Based on Platelet Function Testing

Presenter: 228579|Daniel Aradi

January 29, 2014

Presentation

Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch from Ongoing Clopidogrel to Ticagrelor in ACS Patients

Presenter: G. Caiazzo

January 28, 2014

Presentation

Meta-analysis of Randomized Controlled Trials on the Risk of Bleeding with Dabigatran

Presenter: B.J. Bloom

January 06, 2014

Presentation

Transport to Primary PCI vs. On-site Fibrinolysis Is Independent Predictor of Functional Status after MI

Presenter: D.M. Bilkova

December 16, 2013

Presentation

Preoperative Statins and Limb Salvage after Lower Extremity Revascularization in the Medicare Population

Presenter: Todd R. Vogel

December 11, 2013

Presentation

Impact of Worsening Renal Dysfunction on the Comparative Efficacy of Bivalirudin and Platelet GPIs

Presenter: E. Perdoncin

December 10, 2013

Presentation

Effect of Remote Ischemic Preconditioning (IPC) on Platelet Activation and Reactivity Induced by Ablation for A-Fib

Presenter: A. Stazi

December 09, 2013

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation

Combining Anticoagulant and Antiplatelet Treatment in Patients with Atrial Fibrillation Undergoing PCI - How to Minimize Bleeding and Ischemic Risks?

Presenter: Eli Lev

December 01, 2013

Presentation

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Presenter: Martin T. Rothman

December 01, 2013

Presentation

A Randomised Controlled Trial of Platelet Activity Before and After Cessation of Clopidogrel in Patients with Stable Cardiovascular Disease

Presenter: Isobel Ford

November 12, 2013

Presentation TCT 2013

The Conundrum of Switching DAPT

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

Presenter: Roxana Mehran

October 31, 2013

Presentation TCT 2013

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Presenter: Michelle O'Donoghue

October 31, 2013

Presentation TCT 2013

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

Presentation TCT 2013

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

Presenter: Paul Gurbel

October 31, 2013

Presentation TCT 2013

Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year!

Presenter: Edoardo Camenzind

October 31, 2013

Presentation TCT 2013

New Insights Into High Platelet Reactivity and the Existence of a Therapeutic Window: ADAPT-DES 2-Year Results

Presenter: Ajay Kirtane

October 31, 2013

Presentation TCT 2013

Does Dabigatran Increase MI in Patients with Coronary Artery Disease? Addressing the Current Controversy

Presenter: Michael Ezekowitz

October 31, 2013

Advertisement

Optimizing P2Y12-Receptor Inhibition in ACS Patients Based on Platelet Function Testing

Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch from Ongoing Clopidogrel to Ticagrelor in ACS Patients

Meta-analysis of Randomized Controlled Trials on the Risk of Bleeding with Dabigatran

Transport to Primary PCI vs. On-site Fibrinolysis Is Independent Predictor of Functional Status after MI

Preoperative Statins and Limb Salvage after Lower Extremity Revascularization in the Medicare Population

Impact of Worsening Renal Dysfunction on the Comparative Efficacy of Bivalirudin and Platelet GPIs

Effect of Remote Ischemic Preconditioning (IPC) on Platelet Activation and Reactivity Induced by Ablation for A-Fib

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Combining Anticoagulant and Antiplatelet Treatment in Patients with Atrial Fibrillation Undergoing PCI - How to Minimize Bleeding and Ischemic Risks?

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

A Randomised Controlled Trial of Platelet Activity Before and After Cessation of Clopidogrel in Patients with Stable Cardiovascular Disease

The Conundrum of Switching DAPT

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year!

New Insights Into High Platelet Reactivity and the Existence of a Therapeutic Window: ADAPT-DES 2-Year Results

Does Dabigatran Increase MI in Patients with Coronary Artery Disease? Addressing the Current Controversy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content